Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 3,701 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-Small Cell Lung Cancer Clear all

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 16
States / cities: Birmingham, Alabama • Farmington, Connecticut • Stamford, Connecticut + 13 more

Conditions: Lung Cancer
Interventions: cetuximab, docetaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 77
States / cities: Anchorage, Alaska • Los Angeles, California • Marysville, California + 55 more

Conditions: Pancreatic Cancer, Mesothelioma, Ovarian Cancer, Non-Small Cell Lung Cancer
Interventions: MORAb-009; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • Bethesda, Maryland • Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium chloride); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Sacituzumab tirumotecan, Pemetrexed, Carboplatin, H1 Receptor Antagonist, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 17
States / cities: Oakland, California • Roseville, California • San Francisco, California + 13 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Cisplatin; Drug
Lead sponsor: Southwestern Regional Medical Center; Other
Eligibility: 20 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab; Procedure · Drug · Other + 2 more
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: docetaxel; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2008
U.S. locations: 72
States / cities: Anniston, Alabama • La Jolla, California • San Diego, California + 52 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Sotorasib, 960 mg, oral daily dose for 4 weeks (28 days); Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib, Ramucirumab; Procedure · Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 454
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 360 more

Conditions: Neoplasm Metastasis
Interventions: CC-90003; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Los Angeles, California • New Haven, Connecticut • Charlotte, North Carolina + 1 more

Conditions: Solid Tumor
Interventions: PF-07284892, lorlatinib, binimetinib, cetuximab, encorafenib; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Detroit, Michigan + 6 more

Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions: JDQ443, TNO155, tislelizumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Pittsburgh, Pennsylvania + 1 more

Conditions: Lung Neoplasms, Carcinoma, Non-small Cell Lung
Interventions: axitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 10
States / cities: Irvine, California • Orange, California • Chicago, Illinois + 7 more

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: RO5126766; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 3
States / cities: Miami, Florida • New York, New York • Allentown, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Not listed
Lead sponsor: Medical Prognosis Institute A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 2
States / cities: Birmingham, Alabama • Buffalo, New York

Conditions: Lung Cancer
Interventions: bronchoalveolar lavage, screening questionnaire administration, sputum cytology, bronchoscopic and lung imaging studies, bronchoscopy, computed tomography, study of high risk factors; Other · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: carboplatin, celecoxib, gemcitabine hydrochloride, zileuton; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 75
States / cities: Anniston, Alabama • La Jolla, California • Los Angeles, California + 55 more

Conditions: Head and Neck Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
Interventions: cisplatin, dimesna, paclitaxel; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 3
States / cities: Chicago, Illinois • Baltimore, Maryland • Buffalo, New York

Conditions: Lung Cancer
Interventions: pyrazoloacridine; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Non-Small Cell Lung Cancer
Interventions: Gemcitabine, Cisplatin, IMC-A12 (cixutumumab), Cetuximab, Carboplatin; Drug · Biological
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 12
States / cities: Anniston, Alabama • La Jolla, California • Orange, California + 6 more

Conditions: Precancerous Condition, Stage I Non-small Cell Lung Cancer, Tobacco Use Disorder
Interventions: sulindac, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 79 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 5
States / cities: Scottsdale, Arizona • Tampa, Florida • Burlington, Massachusetts + 2 more

Conditions: Advanced or Metastatic Solid Tumors
Interventions: IPH4502; Drug
Lead sponsor: Innate Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more

Conditions: Lung Cancer
Interventions: Erlotinib, Satraplatin; Drug
Lead sponsor: Agennix; Industry
Eligibility: 70 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 11
States / cities: Anaheim, California • La Jolla, California • Los Angeles, California + 8 more

Search by objective public record fields.

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Docetaxel in Treating Patients With Solid Tumors

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

PF-07284892 in Participants With Advanced Solid Tumors

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer

RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

DNA Chip Based Prognosis of Lung Cancer

Computed Tomography for Early Detection of Cancer in Women Who Are at Risk for Lung Cancer

Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer

Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel

Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)